You are here: Home » PTI Stories » National » News
Business Standard

Sequent to acquire Turkey's animal health firm Topkim

Press Trust of India  |  New Delhi 

Drug firm Sequent Scientific today said its subsidiary Alivira Animal Health will acquire Turkey's Topkim for 20.7 million Turkisk Lira (over Rs 48 crore).

The acquisition will be made through Provet Veterinary Products, a subsidiary of Alivira, Sequent Scientific said in a a regulatory filing.

The transaction has been valued at the enterprise valuation of Turkish Lira 20.7 million, it added.

"As part of our strategy to create a global animal healthcare company, we have been working towards establishing strong foot prints in selected emerging and regulated markets," Alivira's Managing Director Manish Gupta said.

The company recently doubled its business in India and this acquisition now makes the firm the largest animal health player in Turkey, he added.

"Both India and Turkey are strong cattle markets. Going forward you will see Sequent/Alivira making some significant strategic moves in this direction," Gupta said.

Topkim has over 67 registered products that include ectoparasiticides, endectocides and injectable antibiotics.

It has wide distribution capabilities with presence in every sales point in Turkey. The company registered sales of Turkish Lira 21.8 million in FY 2014.

The acquisition would help Sequent to consolidate presence in the USD 400 million Turkish veterinary market, which is growing at around 8 per cent year on year.

Turkey is among the top ten ruminant market and overall it is the 16th largest veterinary market in the world. The combined entity (Provet and Topkim) would make Alivira the largest animal health company in Turkey.

The move would help Alivira to double its business in Turkey with more than 10 per cent market share. It would also provide significant cost synergies for combined operations.

"Topkim's product portfolio is complementary to Provet's business and the combined entity will consolidate the company's market position in Turkey and also benefit from cost synergies," Provet Chairman Huseyin Aydin said.

Sequent shares were trading at Rs 968.75 a piece, up 6.87 per cent, on BSE.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Mon, November 23 2015. 13:57 IST